Clover Health Investments Corp. (NASDAQ:CLOV) finished Wednesday with a subtraction of -$0.03 to close at $1.30, a downside of -2.26 percent. An average of 3,551,760 shares of common stock have been traded in the last five days. There was a fall of -$0.1100 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 6,285,485 shares traded, while the 50-day average volume stands at 9,838,740.
CLOV stock has increased by 19.27% in the last month. The company shares reached their 1-month lowest point of $1.0600 on 07/26/23. With the stock rallying to its 52-week high on 08/09/23, shares of the company touched a low of $0.71 and a high of $3.04 in 52 weeks. It has reached a new high 12 times so far this year and achieved 39.86% or $0.3705 in price. In spite of this, the price is down -57.24% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Clover Health Investments Corp. (CLOV) stock’s beta is 1.94. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.23, the price-to-book (PB) ratio at 1.88, and the price-to-cash flow ratio at 32.31.
Financial Health
The quick ratio of Clover Health Investments Corp. for the three months ended June 29 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $22.73 million compared to revenue of $3.48 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Clover Health Investments Corp.’s return on assets was -20.50%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$28.81 million in the quarter, while revenues of -$72.61 million were shrunk -261.61%. The analyst consensus anticipated Clover Health Investments Corp.’s latest quarter earnings to come in at -$0.15 per share, but it turned out to be -$0.06, a 60.00% surprise. For the quarter, EBITDA amounted to -$29.03 million. Shareholders own equity worth $484.86 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Clover Health Investments Corp. (CLOV) price momentum. RSI 9-day as of the close on 23 August was 46.98%, suggesting the stock is Neutral, with historical volatility in this time frame at 92.56%.
As of today, CLOV’s price is $1.3360 -7.80% or -$0.1100 from its 5-day moving average. CLOV is currently trading +14.04% higher than its 20-day SMA and +57.63% higher than its 100-day SMA. However, the stock’s current price level is +36.10% above the SMA50 and -8.45% below the SMA200.
The stochastic %K and %D were 31.11% and 35.08%, respectively, and the average true range (ATR) was 0.1209. With the 14-day stochastic at 26.67% and the average true range at 0.1183, the RSI (14) stands at 52.38%. The stock has reached -0.0767 on the 9-day MACD Oscillator while the 14-day reading was at -0.0507.
Analyst Ratings
Cowen upgraded Clover Health Investments Corp. (NASDAQ: CLOV) to a a Market perform rating in its most recent analyst report. Previously, the stock was rated as an Underperform. The consensus rating for Clover Health Investments Corp. (CLOV) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell CLOV, while 3 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is CLOV’s price target for the next 12 months?
Analysts predict a range of price targets between $0.90 and $3.00, with a median target of $1.50. Taking a look at these predictions, the average price target given by analysts for Clover Health Investments Corp. (CLOV) stock is $1.65.
